Serum platelet, MPV, PCT and PDW values, neutrophil to lymphocyte and platelet to lymphocyte ratios in lung cancer diagnosis

Abstract

Aim: Inflammation seems to play a critical role in the development and progression of numerous cancers by promoting cancer cell proliferation and angiogenesis. Based on this knowledge, several inflammatory markers in blood count [platelet, neutrophil and lymphocyte, neutrophil to lymphocyte ratio (NLR) and platelet to lymphocyte ratio (PLR), mean platelet volume (MPV), plateletcrit (PCT) and platelet distribution width (PDW)] have been studied in various malignant tumors. The aim of this study was to examine these inflammatory markers could be useful to differentiate lung cancer patients from healthy controls. Methods: Lung cancer patients (n=130) and healthy subjects (n=50) included into the study. Patients with chronic infection, hypertension, hematological and renal disease, heart failure, hepatic disorder and other cancer were excluded from the study. The preoperative or pretreatment blood count data was obtained from the recorded computerized database. Results: Platelet, PCT, neutrophil, NLR and PLR values were significantly higher in the LC patients compared to the healthy subjects (p 0.05). The statistically significant relationship was not determined between these markers and histopathological subgroups (p>0.05). According to TNM staging, these markers (except neutrophil) were statistically significant relationship in the advanced stage compared to the early stage (p Conclusion: Platelet, PCT, MPV,NLR and PLR can be useful biomarkers in the diagnosis of LC.